Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Management and Challenges in Gynecological Cancer
share announcement

Management and Challenges in Gynecological Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (25 May 2023) | Viewed by 4237

Special Issue Editors

Dr. Ahmad Sayasneh

E-Mail Website
Guest Editor
1. Associate Professor, Department of Gynaecological Oncology, Guy’s and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK
2. Faculty of Life Sciences & Medicine at Guy’s, The School of Life Course Sciences, King’s College London, London WC2R 2LS, UK
Interests: ultrsonography; gynaecological cancer; radical and supraradical surgery for gynae cancer; robotics and minimal access surgery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Zelal M. Muallem

E-Mail Website
Guest Editor
1. Department of Gynecology with Center for Oncological Surgery, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
2. Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany
Interests: gynecologic oncology; minimally invasive surgical techniques; reproductive endocrinology; early disease detection and screening methodologies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As you most likely already know, gynaecological cancer treatment is developing globally. Researchers are examining the efficacy of new surgical and non-surgical methods for maintaining fertility in women with gynecological malignancies. Nerve preservation is now a standard part of cervical cancer surgery. The genetic subtyping of endometrial cancer provides the basis for a unique treatment method. Without a question, research into the biology of ovarian cancer has enhanced our understanding of the illness and our capacity to treat it. Defeating the specific challenges presented by gymaecological cancer would almost certainly boost cancer patients' chances of survival. Medical experts are urged to support articles that give in-depth evaluations of gynaecological cancer management challenges and advances, as well as recent research achievements in the area, for this Special Issue.

Dr. Ahmad Sayasneh
Dr. Mustafa Zelal Muallem
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological oncology
  • cancer diagnostics
  • nerve preservation
  • fertility preservation

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 3582 KiB  
Article
Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting
by Zena Alizzi, Patricia Roxburgh, Douglas Cartwright, Alistair McLaren, Sarah Park, Rachel Jones, Semini Greening, Emma Hudson, Clare Green, Simon Gray, Saira Khalique, Emmanouil Karteris and Marcia Hall
J. Clin. Med. 2023, 12(7), 2497; https://doi.org/10.3390/jcm12072497 - 25 Mar 2023
Viewed by 1242
Abstract
Background: The incidence of brain metastases (BM) in patients with epithelial ovarian cancer (EOC) is low: 0.3–11%. The onset of BM has been regarded as a late event with limited treatment options and poor prognosis. This retrospective case series aims to explore the [...] Read more.
Background: The incidence of brain metastases (BM) in patients with epithelial ovarian cancer (EOC) is low: 0.3–11%. The onset of BM has been regarded as a late event with limited treatment options and poor prognosis. This retrospective case series aims to explore the current management strategies with particular emphasis on the use of PARP inhibitors and outcomes, as well as identification of other prognostic indicators. Methods: A total of 39 ovarian cancer patients with brain metastases were identified from eight cancer centres in the UK. Clinical characteristics, details of management, and survival data were collected. Results: A total of 14/39 had BM as their first site of relapse. The majority (29 patients) received systemic treatments in addition to local radiotherapy (RT)/surgery. Nineteen patients had BRCA mutations (one somatic), one had a RAD51C mutation, and eighteen were BRCA wild type; one was unknown. A total of 14/39 patients received maintenance PARP inhibitors. As is well known, patients who received PARPi had consistently better outcomes. This was no different for those who received PARPi as part of the management of their BM. Platinum sensitivity and receiving more than one modality of therapy (e.g., radiation +/− chemotherapy and PARPi) for BM were also good prognostic indicators. Median PFS/OS for those treated with chemotherapy and either RT or surgery, then PARP inhibitor maintenance, have not been reached after a median of 33 months follow up. Conclusions: As with abdominal relapse, maintenance treatment with PARP inhibitors also has a valuable role in managing BMs in EOC patients. Full article
(This article belongs to the Special Issue Management and Challenges in Gynecological Cancer)
►▼ Show Figures

Figure 1

10 pages, 527 KiB  
Article
The Association of Preoperative PET-CT and Survival in Patients with Resectable Cervical Cancer
by Chih-Hsiung Su, Wan-Ming Chen, Ming-Chih Chen, Ben-Chang Shia and Szu-Yuan Wu
J. Clin. Med. 2022, 11(23), 7143; https://doi.org/10.3390/jcm11237143 - 01 Dec 2022
Viewed by 1314
Abstract
Purpose: No randomized study with a long-term follow-up has investigated the effect of pretreatment 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG-PET–CT) on the survival of patients with stage IB-IIA cervical cancer receiving curative surgery. Therefore, in this propensity score–matched, population-based cohort study, [...] Read more.
Purpose: No randomized study with a long-term follow-up has investigated the effect of pretreatment 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG-PET–CT) on the survival of patients with stage IB-IIA cervical cancer receiving curative surgery. Therefore, in this propensity score–matched, population-based cohort study, we investigated the effect of preoperative 18FDG-PET–CT on the survival outcomes of patients with potentially resectable cervical cancer. Patients and Methods: We included 2550 patients with stage IB-IIA cervical cancer receiving curative surgery with complete data on clinical stages. The patients were categorized into two 1:4 propensity, score–matched groups depending on whether they underwent pretreatment 18FDG-PET–CT, and their outcomes were compared. Results: We included 2030 and 520 patients with cervical cancer in the non-pretreatment and pretreatment PET–CT groups, respectively. Multivariable analyses revealed that the most prominent correlation between preoperative PET–CT and all-cause death was observed in the patients with stage IB–IIA cervical cancer receiving surgery (aHR [95% CI]: 1.16 [0.83–1.63]; p = 0.3752). Conclusions: Preoperative 18FDG-PET–CT was not associated with longer survival in the patients with clinical stage IB–IIA cervical cancer receiving curative surgery. Full article
(This article belongs to the Special Issue Management and Challenges in Gynecological Cancer)
►▼ Show Figures

Figure 1

8 pages, 193 KiB  
Article
Gynae-Oncology Surgeons’ Preparedness to Undertake Colorectal Procedures during Cytoreductive Surgery for Ovarian Cancer: A Cross Sectional Survey
by Daniel Huddart, Savithri Rajkumar, Desiree Kolomainen, Gautam Mehra, Rahul Nath and Ahmad Sayasneh
J. Clin. Med. 2022, 11(21), 6233; https://doi.org/10.3390/jcm11216233 - 22 Oct 2022
Viewed by 1124
Abstract
Cytoreductive surgery for advanced ovarian cancer commonly involves bowel resection. Although UK gynaecological oncologists are trained in bowel surgery, the degree to which they perform bowel surgery independently varies nationally. A recent joint policy statement from the British Gynaecological Cancer Society (BGCS) emphasises [...] Read more.
Cytoreductive surgery for advanced ovarian cancer commonly involves bowel resection. Although UK gynaecological oncologists are trained in bowel surgery, the degree to which they perform bowel surgery independently varies nationally. A recent joint policy statement from the British Gynaecological Cancer Society (BGCS) emphasises the need for formalised colorectal support. An anonymous, online survey was emailed to BGCS members to assess the status of multidisciplinary working between UK gynaecological oncology and colorectal/general surgical teams. A total of 46 members responded (8.2% response rate). There was a large variety in the involvement of colorectal/general surgical teams in preoperative planning. A total of 13% of respondents had no formalised agreement for intraoperative support, 72.1% of respondents independently performed rectal peritoneal stripping and 60.5% independently performed small bowel resection. This was reduced to 27.9% for right hemicolectomy with primary anastomosis and 16.3% for left hemicolectomy with primary anastomosis. Respondents often involved colorectal support for post-operative complications. The majority of UK gynaecological oncologists involve colorectal/general surgical teams in bowel procedures, more commonly for large bowel procedures compared to small bowel and for left colon compared to right colon procedures. A total of 16.3% of respondents independently performed all surveyed bowel procedures. Future research should examine training and experience within these groups to address this disparity. Full article
(This article belongs to the Special Issue Management and Challenges in Gynecological Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop